Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 22
GLP-1 and GIP Obesity Drugs: Evidence
A source-led guide to the evidence, safety limits, and unanswered questions around GLP-1 and dual GIP/GLP-1 obesity medicines.
Mounjaro hair loss: what trials show
Tirzepatide weight loss trials recorded hair loss in 4% to 5% of participants, compared with 1% on placebo.
Tirzepatide and Smoking Aversion
A 2026 case report linked tirzepatide initiation with abrupt sensory aversion to cigarettes and two years of reported smoking abstinence.
Why Weight Loss Can Slow on Tirzepatide
A slower scale trend on tirzepatide can have several meanings. Here is what trials show, what the scale misses, and when to seek clinical review.
Diabetes Drugs and Cardiovascular Outcomes
A 93-trial network meta-analysis linked several diabetes drug classes with fewer cardiovascular events, while indirect comparisons limit treatment rankings.
GLP-1s and Neurodegeneration Reviewed
A 2026 narrative review finds biological promise for GLP-1-related drugs in neurodegeneration, but no established disease-modifying benefit.
GLP-1 Use in Serious Mental Illness
A 218,043-person retrospective cohort linked GLP-1 use with lower cardiovascular event and death risks in serious mental illness.
MASLD and MASH Drug Review
A 2026 narrative review separates approved MASH therapies from emerging candidates, including tirzepatide, while warning against cross-trial rankings.
Retatrutide Adverse Effects Online
A 2026 retatrutide social media study mapped self-reported symptoms but could not verify products, incidence, or causation.
GLP-1 Safety Knowledge: Student Survey
A Saudi pharmacy-student survey found a mean GLP-1 safety knowledge score of 7.6 out of 17, with a 26.5% response rate.
GLP-1 Use Before Bariatric Surgery
An editorial highlights a matched cohort linking prior GLP-1 or tirzepatide use with fewer early cardiorenal events after surgery.
Semax Glaucoma Cohort Readout
A 50-patient glaucoma surgery cohort found a visual-field signal with bundled physiotherapy, but it could not isolate an effect of Semax.